[DOI] [PMC free article] [PubMed] [Google Scholar] 33.Li J, Wu Z, Zhao L, Liu Y, Su Y, Gong X, Liu F, Zhang L
As with any orthopedic injury, a consultation with a sports medicine professional is recommended
Tesamorelin vs CJC-1295/Ipamorelin at a Glance Tesamorelin FDA Status FDA-approved (Egrifta, November 2010) CJC-1295/Ipam FDA Status Compounded (CJC-1295 reached Phase 2) Tesamorelin Mechanism GHRH receptor only (DPP-IV protected) CJC-1295/Ipam Mechanism GHRH + ghrelin receptor (dual pathway) Strongest Evidence Tesamorelin: 2 Phase 3 RCTs, 816 patients, CT-measured fat Most Popular CJC-1295/Ipamorelin (dual pathway, broader benefits) The Core Difference Tesamorelin and CJC-1295 both bind the GHRH receptor on pituitary somatotroph cells to stimulate growth hormone release
Popular FAQ Which GLP-1 drug is best for weight loss
What are its hair and scalp benefits